Sweden's Magle Chemoswed posts prelim Q3 net loss on write-down, financing costs

Overview

• Sweden contract manufacturing and biopolymer firm's preliminary Q3 net sales were SEK 70.9 mln

• Company reported SEK 107.1 mln net loss in Q3, with EBIT at SEK -45 mln

• Q3 results impacted by SEK 26 mln inventory write-down and SEK 60 mln financing costs

Outlook

• Company will publish a simplified Q3 report by 30 Nov 2026 for bondholders

• Company will not publish a standard Q3 2026 report under Nasdaq First North rules

• Preliminary Q3 figures may differ from those in the upcoming simplified report

Result Drivers

• INVENTORY WRITE-DOWN - SEK 26 mln write-down of obsolete inventory charged to raw materials and consumables

• REFINANCING COSTS - SEK 4 mln in refinancing costs charged to operating expenses in Q3

• FINANCING COSTS - SEK 60 mln in financing-related costs tied to bond refinancing and share issues

Company press release:

Key Details

Analyst Coverage

• Wall Street's median 12-month price target for Magle Chemoswed Holding AB is SEK1.00, about 478% above its November 3 closing price of SEK0.17

• The stock recently traded at 0 times the next 12-month earnings vs. a P/E of 0 three months ago

Reuters Recommended Reads

• Nov 3 - Sweden's SynAct Pharma Q3 net loss narrows as expenses fall

• Nov 3 - Sweden's Serstech Q3 sales more than double, returns to profit

• Nov 3 - Sweden's Flat Capital Q3 NAV falls as Klarna share decline weighs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)